Preparation of new half sandwich ruthenium arene complexes with aminophosphines as potential chemotherapeutics

Aliende, Cristina; Pérez-Manrique, Mercedes; Jalón, Félix A.; Manzano, Blanca R.; Rodrı́guez, Ana; Cuevas, José V.; Espino, Gustavo; Martínez, Ma Ángeles; Massaguer, Anna; González-Bártulos, Marta; Llorens, Rafael de; Moreno, Virtudes

doi:10.1016/j.jinorgbio.2012.07.022

Cited by 35 publications

(23 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 So far, two ruthenium-based drugs, NAMI-A 5 ( Figure 1A) and KP1019 6 ( Figure 1B 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 4 complexes with structurally simple diketonates such as acetylacetonate had reasonable activity toward the A2780 cell line, there was only minor follow-up research done in this area. 7,10,11 Similar complexes with symmetric alkyl and aryl substituted diketonates and the phosphine ligand pta were reported to exhibit high cytotoxicity in combination with low hydrolysis rates, 10,11 while the prototype compound [(η 6 -p-cymene)Ru(pta)Cl 2 ] (RAPTA-C) remains the best anticancer organometallic compound of this series ( Figure 1D). 4,12,13 …”

mentioning

confidence: 76%

Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates

et al. 2015

View full text Add to dashboard Cite

A series of organoruthenium(II) chlorido complexes with fluorinated O,O-ligands [(η(6)-p-cymene)Ru(F3C-acac-Ar)Cl] (1a-6a) and their respective 1,3,5-triaza-7-phosphaadamantane (pta) derivatives [(η(6)-p-cymene)Ru(F3C-acac-Ar)pta]PF6 (1b-6b) were synthesized and fully characterized in both solution and solid state. All complexes were inactive against nonmalignant keratinocytes but displayed variable activity against cancer cell models (ovarian, osteosarcoma). Compounds with a ligand containing the 4-chlorophenyl substituent (6a and 6b) exhibited the strongest anticancer effects. Despite a marginally lower cellular Ru accumulation compared to the chlorido complexes, pta analogues showed higher activity especially in the osteosarcoma model. Reduction of glutathione levels by buthionine sulfoximine (BSO) significantly enhanced the activity of all compounds with the most pronounced effects being observed for the pta series resulting in IC50 values down to the nanomolar range. While all chlorido complexes potently induce reactive oxygen species, DNA damage, and apoptosis, the respective pta compounds widely lacked ROS production but blocked cell cycle progression in G0/G1 phase.

show abstract

mentioning

confidence: 76%

Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The tetrafluoroborate derivatives 36 , 38 , 40 , 44 and 46 were selected for evaluation of their cytotoxic behaviour against MCF‐7 (breast cancer) and CAPAN‐1 (pancreatic cancer) cell lines. The most active complexes in both cell lines are those containing the diphenyl‐2‐pyridylphosphine ligand, which also exhibit a notable interaction with DNA …”

Section: Half‐sandwich Metal Complexes With Oo‐chelating Ligandsmentioning

confidence: 99%

Half‐Sandwich Metal Complexes with β‐Diketone‐Like Ligands and Their Anticancer Activity

et al. 2018

View full text Add to dashboard Cite

show abstract

“…4b. [30] By modulating the nature of the Rg roup, it is possible to tune the activity,the best results being achievedwith the pyridine species. These are supposed to quickly release the β-diketonate moiety in aqueous environment, possibly due to the donor ability of the pyridine group activating the complex.…”

Section: Rumentioning

confidence: 99%

Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents

Biancalana

Pampaloni

Marchetti

2017

Chimia

View full text Add to dashboard Cite

Ruthenium(II) complexes of formula [Ru(η6-arene)Cl2 (PTA)] (RAPTA) are potential anticancer drugs with notable antimetastatic and antiangiogenic activity, which are now pointing to clinical trials. Following the great interest aroused by these compounds, a variety of RAPTA derivatives, obtained by chloride substitution and/or containing functionalized arene ligands, and complexes resembling the RAPTA structure but bearing different phosphorous ligands have been synthesized and evaluated for their anticancer activity. An overview of all of these biologically relevant complexes will be given, with particular reference to the anticancer behaviour exhibited by the compounds and the possible relationship with structural aspects.

show abstract

Preparation of new half sandwich ruthenium arene complexes with aminophosphines as potential chemotherapeutics

Cited by 35 publications

References 72 publications

Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates

Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates

Half‐Sandwich Metal Complexes with β‐Diketone‐Like Ligands and Their Anticancer Activity

Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents

Contact Info

Product

Resources

About